CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 94 enrolled
Drug / intervention
individualized Stereotactic Body Radiation Therapy (SBRT)radiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01522937
NCT01522937Phase 2Completed
CompareCT.gov

A Phase II Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer

University of Michigan Rogel Cancer Center·interventional·Posted Feb 1, 2012·Updated Mar 9, 2017

In Brief

A Phase 2 clinical trial evaluating individualized Stereotactic Body Radiation Therapy (SBRT) for Liver Cancer and Hepatocellular Cancer. Completed, enrolled 94 participants across 1 site.

Detailed Summary

This is a Phase II trial to characterize the safety and efficacy of individualized stereotactic body radiation therapy (SRBT) for patients who have had previous liver treatment or who have primary hepatocellular carcinoma (HCC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer, Hepatocellular Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 1, 2012
Enrollment StartOct 1, 2009
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 14.4 years ago

Interventions

individualized Stereotactic Body Radiation Therapy (SBRT)radiation

The individualized SBRT involves two treatment phases. The first phase of treatment involves receiving three fractions of SBRT, followed by a 1-month break and assessment of liver function with a blood test - Indocyanine Green (IC-Green). The second phase of treatment involves receiving two more fractions of SBRT, whose doses are adjusted to account for tolerance of the first phase of treatment.